Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51895 | 0.93 | RNASEH1 (0.42) | RNASEH1ROCK2ADORA3ERCC1FEN1 | |
| SCHEMBL63358 | 0.91 | RNASEH1 (0.43) | RNASEH1ROCK2ADORA3ERCC1FEN1 | |
| SCHEMBL52899 | 0.91 | RNASEH1 (0.41) | RNASEH1ROCK2ADORA3ERCC1FEN1 | |
| SCHEMBL62555 | 0.89 | RNASEH1 (0.43) | RNASEH1ROCK2ADORA3ERCC1FEN1 | |
| SCHEMBL63486 | 0.88 | RNASEH1 (0.42) | RNASEH1ROCK2ADORA3ERCC1FEN1 | |
| SCHEMBL52441 | 0.87 | RNASEH1 (0.45) | RNASEH1ROCK2ADORA3ERCC1FEN1 | |
| SCHEMBL63444 | 0.85 | RNASEH1 (0.43) | RNASEH1ROCK2ADORA3ERCC1FEN1 | |
| SCHEMBL9942868 | 0.84 | RNASEH1 (0.42) | RNASEH1ROCK2ADORA3ERCC1FEN1 | |
| SCHEMBL51972 | 0.84 | RNASEH1 (0.42) | RNASEH1ROCK2ERCC1FEN1ERCC4 | |
| SCHEMBL2080700 | 0.84 | RNASEH1 (0.42) | RNASEH1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | RNASEH1 1285/4885ROCK2 1690/4885ADORA3 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.